Market Signal Briefing

XRP price started a recovery wave above $1.380 but failed near $1.3980. The price is now consolidating and might aim for a fresh move above $1.40.

XRP price started a recovery wave above the $1.3750 zone. The price is now trading below $1.40 and the 100-hourly Simple Moving Average. There is a bearish trend line forming with resistance at $1.4100 on the hourly chart of the XRP/USD pair (data source from Kraken). The pair could continue to move up if it settles above $1.40. XRP Price Faces Key Hurdle XRP price remained supported above $1.3120 and started a recovery wave, like Bitcoin and Ethereum. The price was able to climb above $1.3350 and $1.350 to enter a short-term positive zone.

There was also a move above the 50% Fib retracement level of the downward move from the $1.4244 swing high to the $1.3125 low. The bulls even pushed the price above $1.38 but they struggled to keep the price above $1.3950. Besides, there is a bearish trend line forming with resistance at $1.410 on the hourly chart of the XRP/USD pair.

The price is now trading below $1.40 and the 100-hourly Simple Moving Average. If there is a fresh upward move, the price might face resistance near the $1.3980 level or the 76.4% Fib retracement level of the downward move from the $1.4244 swing high to the $1.3125 low.

Source: XRPUSD on TradingView.com The first major resistance is near the $1.4050 level. A close above $1.4050 could send the price to $1.4120. The next hurdle sits at $1.4250. A clear move above the $1.4250 resistance might send the price toward the $1.450 resistance. Any more gains might send the price toward the $1.50 resistance.

Another Drop? If XRP fails to clear the $1.40 resistance zone, it could start a fresh decline. Initial support on the downside is near the $1.3650 level. The next major support is near the $1.350 level.

If there is a downside break and a close below the $1.350 level, the price might continue to decline toward $1.3320. The next major support sits near the $1.3220 zone, below which the price could continue lower toward $1.3120.

Technical Indicators

Hourly MACD – The MACD for XRP/USD is now gaining pace in the bullish zone.

Hourly RSI (Relative Strength Index) – The RSI for XRP/USD is now above the 50 level.

Major Support Levels – $1.3650 and $1.3500.

Major Resistance Levels – $1.4000 and $1.4120.

Why Trust CoinGape

CoinGape has covered the cryptocurrency industry since 2017, aiming to provide informative insights to our readers. Our journal analysts bring years of experience in market analysis and blockchain technology to ensure factual accuracy and balanced reporting. By following our Editorial Policy, our writers verify every source, fact-check each story, rely on reputable sources, and attribute quotes and media correctly. We also follow a rigorous Review Methodology when evaluating exchanges and tools. From emerging blockchain projects and coin launches to industry events and technical developments, we cover all facets of the digital asset space with unwavering commitment to timely, relevant information.

Stripe, a traditional payments giant, is reportedly considering a deal to acquire PayPal Holdings, which may potentially result in one of the biggest fintech mergers in recent years. The two companies are currently conducting their initial acquisition discussions, but they have not yet reached a definitive agreement.

The potential partnership has drawn significant attention as both companies expand their collaborations amid the growing convergence of stablecoin and digital payment systems.

How Will the Stripe–PayPal Deal Reshape Digital Payment? According to a Bloomberg report earlier today, Stripe is planning to buy all or part of PayPal Holdings. The report states that the discussions are in the early stages, and it is not clear if the acquisition deal will really happen.

It is worth noting that the move comes close on the heels of Stripe’s tender offer announcement on Tuesday. The company revealed that it reached a $159 billion valuation through a tender offer to shareholders and employees, marking a 74% increase from last year.

This follows Stripe’s Tuesday announcement that it processed $1.9 trillion in annual payment volume. It also secured approval for a U.S. national bank trust charter for Bridge, its stablecoin subsidiary.

At the same time, PayPal has been facing severe challenges over the past few years, with growing competition from its rivals like Apple Pay and Google Pay. These platforms come with pre-installed applications on most smartphones, which makes them deeply integrated into users’ daily transactions.

As mobile wallets have become the default payment option, PayPal has struggled to maintain the same level of growth. Commenting on PayPal’s concerning situation, Stripe president John Collison stated,

“PayPal has had, obviously, a tough time over the past few years and the landscape has changed quite a bit with Apple Pay and Google Pay and everything like that…I can’t talk about any, you know, M&A hypotheticals but they’ve definitely had a tough time.”

PayPal is constantly facing scrutiny from public investors for its failure to compete with its rivals. It has also failed to deliver strong quarterly earnings. So, if the Stripe-Paypal acquisition is realized, it could give PayPal relief from market pressure and intense competition.

According to Tiger Research’s Ryan Yoon, the collaboration is “a vertical integration of legacy infrastructure and modern API stacks.” He believes that the deal offers PayPal “an exit from public market scrutiny and Big Tech competition, while giving Stripe immediate access to massive enterprise liquidity.”

Deepening Stablecoin Push Amid Global Payments Shift The move pushes Stripe deeper into the regulated stablecoin space. It also aligns with the growing use of digital assets in the global payments system.

In recent years, cryptocurrencies and stablecoins have been increasingly used for faster cross-border payments, on-chain settlements, and treasury management. For instance, as CoinGape reported, Mark Zuckerberg’s Meta is exploring stablecoin integration this year amid growing regulatory clarity.

Banks, fintech firms, and traditional payment companies are exploring blockchain-based rails to reduce costs and improve settlement speed. Yesterday, CoinGape reported that SBI Holdings and Ripple are exploring using the XRP Ledger for cross-border payments.

Thus, if the Stripe-PayPal deal moves forward, it could mark another major episode in the growing trend of stablecoin payment systems.

The Ethereum Foundation has made one thing clear this week: it is not backing just any DeFi project with a token and a dashboard.

In a series of posts outlining its direction, the Foundation said it wants to see decentralized finance thrive, but only if it lives up to core principles. As one member put it, DeFi is not just another niche inside crypto.

“DeFi isn’t a speculative bet on the future. It’s the inevitable evolution of finance,” adding that “financial autonomy is a right, not a privilege.”

Ethereum co-founder Vitalik Buterin doubled down on that message.

“DeFi is a central part of the value that Ethereum provides,” Buterin wrote. “Financial empowerment is a central part of what it means to have agency and freedom in our current world.” He said that Ethereum does far more than finance, but stressed that permissionless access to savings, risk management and payments remains one of its strongest contributions.

Not All Onchain Finance Makes the CutButerin was direct about where the line is drawn. The Foundation is not interested in supporting “on-chain finance” indiscriminately. Instead, it wants “permissionless, open-source, private, security-first global finance that maximizes people’s control over their own assets, minimizes centralized chokepoints and trusted third parties.”

One concept he stressed is what he called the “walkaway test.” Protocols should keep functioning even if the founding team disappears or turns hostile. 

Ethereum, he reminded readers, is permissionless. Anyone can deploy anything. But that does not mean the Foundation will stand behind projects that rely on unnecessary centralization or what he described as “dopamine-maximizing gambleslop.”

A Return to DeFi’s EraButerin also called for a revival of the early DeFi mindset. “Ethereum’s early DeFi era was great because it dared to dream and innovate,” he said, pointing to breakthroughs like automated market makers.

Instead of simply building “a better stablecoin,” he requested developers to dig deeper into core problems such as risk management and hedging future expenses, and to design solutions that traditional finance cannot replicate.

Hence, Ethereum wants DeFi that could not exist without Ethereum. Not a copy of traditional finance with a blockchain label, but something structurally different.

Never Miss a Beat in the Crypto World!Stay ahead with breaking news, expert analysis, and real-time updates on the latest trends in Bitcoin, altcoins, DeFi, NFTs, and more.

FAQsWhat is the Ethereum Foundation’s stance on DeFi projects?

The Ethereum Foundation backs DeFi that is permissionless, open-source, secure, and minimizes centralized control, not speculative or heavily centralized projects.

Why doesn’t Ethereum support all on-chain finance projects?

Ethereum supports projects that reduce trusted intermediaries and protect users, not those relying on central control or short-term speculative hype.

How does Ethereum want DeFi to evolve?

Ethereum encourages DeFi that solves real financial problems like risk management and hedging, creating systems traditional finance cannot replicate.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

Recent on-chain data has revealed the fragility of Ethereum's price action, alongside a distinct pattern among accumulating whales.

David Schwartz, Ripple’s Chief Technology Officer (CTO) and one of the original architects of the XRP Ledger (XRPL), has taken to the X social media network to shut down speculation regarding the network's perceived centralization. 

"Objectively nonsensical"As reported by U.Today, Justin Bons, founder of Cyber Capital, posted a scathing thread on X (formerly Twitter), urging the crypto community to "reject all centralized 'blockchains'." He has specifically named Ripple, Stellar, Hedera, and Algorand. 

Bons argued that Ripple’s Unique Node List (UNL) makes it possible for the Ripple Foundation to gain "absolute power" and "control" over the chain.

HOT Stories

Schwartz was quick to shut down this argument, stating that it was "objectively nonsensical."

"...effectively giving the Ripple Foundation & company absolute power & control over the chain..."

This is as objectively nonsensical as claiming someone with a majority of mining power can create a billion bitcoins.

— David 'JoelKatz' Schwartz (@JoelKatz) February 24, 2026 The former Ripple CTO drew a sharp parallel to Bitcoin mining to illustrate the absurdity of the accusation.

You Might Also Like

"This is as objectively nonsensical as claiming someone with a majority of mining power can create a billion bitcoins," Schwartz wrote.

Schwartz has also rejected the idea that it would be possible to double-spend or censor transactions. 

"You count the number of validators that agree with your node, and your node will not agree to double-spend or censor unless you, for some reason, want it to," he said.

Even if validators tried to act maliciously, the network’s design protects honest participants.

He conceded that a conspiracy of validators could theoretically "halt the chain from the point of view of honest nodes." This is the XRPL equivalent of a dishonest majority attack, but they never get to double-spend.

News

Video

PricesResearchConsensus 2026

Data & Indices

SponsoredThe token is consolidating around $0.0940–$0.0945 with higher lows, signaling constructive momentum after the breakout. Feb 25, 2026, 5:53 a.m.

What to know: Dogecoin broke above a key resistance level at $0.0924 on sharply higher volume, turning it into short-term support.The token is consolidating around $0.0940–$0.0945 with higher lows, signaling constructive momentum after the breakout.Traders now see $0.0940 as the line of defense for bulls, with upside targets near $0.0955–$0.0960 and downside risk back toward $0.0924 if the move fails.Dogecoin pushed higher on outsized volume after repeatedly testing resistance, flipping a key ceiling into support and setting up a near-term test of the next supply zone.

News BackgroundDOGE advanced alongside a stabilizing broader crypto market, with buyers stepping in after several sessions of tight consolidation. The move wasn’t driven by token-specific headlines but by technical positioning, as repeated failures at $0.0924 left the level primed for a breakout once liquidity expanded.The rally comes after DOGE spent hours coiling between $0.090 and $0.0927, building compression before volume returned. Open interest remains elevated but not extreme, suggesting moderate leverage participation rather than a crowded speculative push.Price Action SummaryDOGE gained 1.9%, rising from $0.0926 to $0.0944Breakout above $0.0924 occurred on 749M volume, 176% above baselinePrice briefly probed $0.0950 before consolidating near $0.0940–$0.0945Higher lows formed during consolidation, confirming short-term strengthTechnical AnalysisThe key technical development was the sustained break above $0.0924, a level that capped multiple attempts earlier in the session. Once cleared, momentum accelerated quickly, and the breakout volume suggests genuine participation rather than a low-liquidity spike.The subsequent consolidation near $0.0940 appears constructive, with shallow pullbacks and higher lows indicating buyers defending the breakout zone. That keeps short-term structure bullish, but the real test lies at $0.0946–$0.0950, where supply previously absorbed upside attempts.A decisive close above $0.0950 would expose $0.0955–$0.0960. Failure to hold $0.0940 would risk a pullback toward $0.0924, which now serves as the structural pivot.What traders say is next?Traders view $0.0940 as the new line of defense. As long as DOGE holds above that level, momentum favors continuation toward $0.0955 and potentially $0.0960.If the breakout fades and price slips back below $0.0924, the move would resemble a false break, reopening the prior consolidation range and shifting near-term bias back to neutral.More For You

Bitcoin bounces above $65,000 as dollar weakens and bullish hopes build

53 minutes ago

A broad uptick across tokens arrived alongside a softer greenback and a rally in Asian equities, though analysts remain split on whether the Feb. 5 lows will hold.

What to know:

Bitcoin rebounded to about $65,400 as a weaker U.S. dollar and a risk-on rally in Asian equities gave crypto markets their first solid bounce in weeks.The broader crypto market is testing a potential double-bottom pattern that could imply roughly 10% upside if it holds, but a failure to rebound could trigger a further decline of about 25%, according to FxPro's Alex Kuptsikevich.Despite gains in major tokens such as ether, solana and XRP, analysts describe a crisis of confidence in bitcoin after its nearly 50% slide from record highs and warn that real capitulation may still lie ahead.Top Stories

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

Jameson Lopp is escalating his criticism of BIP-110, arguing the proposal could trigger a disruptive Bitcoin chain split while failing to stop the behavior it is meant to curb. In a Feb. 23 post, Lopp frames the plan as a consensus-layer response to a policy and cultural dispute around transaction “spam,” with risks that extend well beyond mempool debates.

BIP-110 is pitched as a soft fork led by Luke Dashjr that would temporarily restrict arbitrary data in transactions. Lopp summarizes it as adding seven new transaction-validity restrictions, including limits on where data can be placed and constraints on certain script behavior, but says the tradeoffs are far more severe than supporters admit. He calls the proposal “reckless and doomed to fail,” setting the tone for a post that is less a technical explainer than a warning about governance and coordination risk.

Why Lopp Thinks The Activation Path Is Dangerous For Bitcoin The core of Lopp’s argument is not just what BIP-110 changes, but how it tries to activate. He points to the proposal’s 55% miner-signaling threshold for a user-activated soft fork and says that low bar materially increases the probability of two competing chains if the ecosystem is not aligned.

He also stresses that BIP-110 nodes would reject non-compliant blocks outright, which raises coordination risk compared with soft forks that old nodes can continue to follow without enforcement conflicts.

Lopp is especially pointed on the mandatory activation posture at block height 961,632. In one of the sharpest passages, he writes: “This is not a neutral, low-drama deployment posture. It’s dogmatic bullying. […] you cannot pretend it’s low-risk.” He ties that warning to a broader point: even if one views UASF tactics as legitimate, the proposal’s design increases the odds of a messy failure mode if miners, exchanges, wallets, and infrastructure providers do not converge in time.

He also pushes back on comparisons to 2017, noting that the UASF many people cite in the SegWit era never actually had to run to the edge because SegWit activated via miner signaling instead. That distinction matters in Lopp’s framing, because BIP-110 proponents are, in his view, leaning on a historical precedent that did not test the exact scenario they now describe as manageable.

Another major section of Lopp’s post targets the claim that BIP-110 has meaningful grassroots momentum. He argues that raw node counts (roughly 20% run Knots) are a weak proxy for consensus because signaling is cheap, node operation can be low-cost, and Tor addresses are “effectively zero” cost to create at scale. He publishes a breakdown of reachable nodes and highlights the higher Tor-to-IPv4 ratio among Knots and BIP-110 signaling nodes as a reason to treat node-count narratives cautiously.

On mining support, Lopp says the gap is more straightforward. At the time of publication, he writes miner signaling was “precisely […] zero,” and he cites public opposition from F2Pool while arguing miners have limited incentive to back a proposal that could reduce fee revenue. That point reinforces his broader thesis that BIP-110 supporters are overestimating social signaling and underestimating the role of economically significant actors in Bitcoin upgrade politics.

Lopp’s post ultimately reads as a warning that the immediate issue is not simply whether BIP-110 activates, but what the campaign reveals about where Bitcoin’s internal dispute over neutrality, censorship resistance, and block-space usage is heading. Even a failed fork push, in his framing, can still impose real costs by forcing operators and businesses to plan around low-probability but high-impact coordination failure.

At press time, Bitcoin traded at $62,791.

Bitcoin falls below $63,000, 1-week chart | Source: BTCUSDT on TradingView.com Featured image created with DALL.E, chart from TradingView.com

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

February 24, 2026 23:13 ET  | Source: Bicara Therapeutics Inc.

BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the pricing of an underwritten public offering of 7,175,000 shares of its common stock at a public offering price of $16.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 2,200,000 shares of common stock at a public offering price of $15.9999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds to Bicara from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Bicara, are expected to be approximately $150 million, excluding any exercise of the underwriters’ option to purchase additional shares and excluding the exercise of any pre-funded warrants. All shares and pre-funded warrants in the offering are being sold by Bicara. The offering is expected to close on or about February 26, 2026, subject to the satisfaction of customary closing conditions. In addition, Bicara has granted the underwriters a 30-day option to purchase up to 1,406,250 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Bicara intends to use the net proceeds of the offering to further invest in and build its medical and commercial infrastructure to support a planned regulatory filing and commercial launch for ficerafusp alfa, if approved, in the U.S.; to further accelerate the development of ficerafusp alfa in 1L R/M HPV-negative HNSCC, including a less frequent dosing schedule; to fund manufacturing costs for ficerafusp alfa for ongoing and anticipated drug development efforts; to fund early signal-finding to support future indication expansion for ficerafusp alfa; and for other general corporate purposes.

Morgan Stanley, TD Cowen, BofA Securities, Cantor and Stifel are acting as joint book-running managers for the offering.

The securities described above will be offered by Bicara pursuant to an effective “shelf” registration statement on Form S-3 (File No. 333-290707) that was filed with the Securities and Exchange Commission (the “SEC”) on October 3, 2025 and declared effective on November 26, 2025. The securities may be offered only by means of a prospectus supplement and an accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the proposed offering will be filed with the SEC. Electronic copies of the preliminary prospectus supplement and, when available, copies of the final prospectus supplement, and the accompanying prospectus relating to the offering may be obtained by visiting the SEC’s website at www.sec.gov or by contacting Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at [email protected]; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected]; BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at [email protected]; Cantor Fitzgerald & Co., Attention: Equity Capital Markets, 110 E. 59th Street, 6th Floor, New York, NY 10022, or by email at [email protected]; or Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at [email protected].

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara’s lead program, ficerafusp alfa, is a first-in-class bifunctional antibody designed to drive tumor penetration by breaking barriers in the tumor microenvironment that have challenged the treatment of multiple solid tumor cancers. Specifically, ficerafusp alfa combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (“TGF-β”). Through this targeted mechanism, ficerafusp alfa reverses the fibrotic and immune-excluded tumor microenvironment driven by TGF-β signaling to enable tumor penetration that drives deep and durable responses. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types.

Forward-Looking Statements
Litigation Reform Act of 1995, as amended. These statements may be identified by words such as “may,” “might,” “will,” “could,” “would,” “should,” “plan,” “anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target” and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all contain identifying words. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, the completion of the underwritten public offering, the potential exercise by the underwriters of the option to purchase additional shares, the anticipated proceeds and use of such proceeds from the offering, and timing of the closing of the offering. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to uncertainties inherent in the development of product candidates, including the conduct of research activities and the conduct of clinical trials; uncertainties as to the availability and timing of results and data from clinical trials; whether results from prior preclinical studies, preliminary or interim data from earlier stage clinical trials will be predictive of the results of subsequent preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; whether Bicara’s cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Bicara’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024, its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 and any subsequent filings Bicara makes with the SEC. In addition, any forward-looking statements represent Bicara’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Bicara explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Contacts:

Investors
Jenna Cohen
[email protected]

Media
Amanda Lazaro
1AB
[email protected]

Herbalife has surged by 138% over the past year, outperforming other staple and Russell 2000 peers, and has now garnered the top SA quant rating in its sector. HLF's topline performance in Q4 was quite impressive, but growth is expected to slow as we progress through FY26, and Pro2col's volume contributions this year are likely to be minimal. HLF's India business could prove to be a dark horse with recent GST changes, but those tax reforms will also reflect badly on HLF's SG&A base.

Vaxcyte, Inc. (PCVX) Q4 2025 Earnings Call Transcript

Alcon (ALC - Free Report) reported $2.7 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 9.1%. EPS of $0.78 for the same period compares to $0.72 a year ago.

The reported revenue represents a surprise of -0.2% over the Zacks Consensus Estimate of $2.71 billion. With the consensus EPS estimate being $0.79, the EPS surprise was -0.76%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Alcon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Net Sales- Total Surgical- Equipment/other: $277 million compared to the $277.54 million average estimate based on four analysts. The reported number represents a change of +21% year over year.Net Sales- Total Surgical- Implantables: $474 million versus $482.1 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +4% change.Net Sales- Total Surgical: $1.55 billion compared to the $1.56 billion average estimate based on four analysts. The reported number represents a change of +8.6% year over year.Net Sales- Total Vision care: $1.16 billion versus the four-analyst average estimate of $1.15 billion. The reported number represents a year-over-year change of +9.8%.Net Sales- Total Surgical- Consumables: $794 million versus the four-analyst average estimate of $796.13 million. The reported number represents a year-over-year change of +7.6%.Net Sales- Total Vision Care- Contact lenses: $683 million compared to the $687.14 million average estimate based on four analysts. The reported number represents a change of +7.1% year over year.Net Sales- Total Vision Care- Ocular health: $474 million compared to the $462.7 million average estimate based on four analysts. The reported number represents a change of +13.9% year over year.Net Sales and other revenues- Other revenues: $16 million versus $26.18 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -36% change.Net Sales and other revenues- Net Sales: $2.7 billion versus $2.7 billion estimated by three analysts on average.View all Key Company Metrics for Alcon here>>>

Shares of Alcon have returned +2.6% over the past month versus the Zacks S&P 500 composite's -1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

For the quarter ended December 2025, MercadoLibre (MELI - Free Report) reported revenue of $8.76 billion, up 44.6% over the same period last year. EPS came in at $11.03, compared to $12.61 in the year-ago quarter.

The reported revenue represents a surprise of +2.86% over the Zacks Consensus Estimate of $8.52 billion. With the consensus EPS estimate being $11.77, the EPS surprise was -6.31%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how MercadoLibre performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Gross merchandise volume: $19.91 billion versus $19.19 billion estimated by four analysts on average.Total payment volume: $83.69 billion compared to the $82.19 billion average estimate based on three analysts.Geographic Revenue- Brazil: $4.64 billion versus $4.48 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +47.9% change.Geographic Revenue- Other countries: $414 million versus $387.14 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +53.9% change.Geographic Revenue- Mexico: $2.1 billion versus $2.13 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +55.6% change.Geographic Revenue- Argentina: $1.61 billion versus $1.67 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +23.3% change.View all Key Company Metrics for MercadoLibre here>>>

Shares of MercadoLibre have returned -15.7% over the past month versus the Zacks S&P 500 composite's -1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

For the quarter ended December 2025, SPX Technologies (SPXC - Free Report) reported revenue of $637.3 million, up 19.4% over the same period last year. EPS came in at $1.88, compared to $1.51 in the year-ago quarter.

The reported revenue represents a surprise of +1.57% over the Zacks Consensus Estimate of $627.44 million. With the consensus EPS estimate being $1.86, the EPS surprise was +0.92%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how SPX Technologies performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Revenues- Detection & Measurement: $206.2 million versus $197.64 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +26.4% change.Revenues- HVAC: $431.1 million versus the five-analyst average estimate of $429.8 million. The reported number represents a year-over-year change of +16.4%.Segment Income- Detection & Measurement: $47.9 million compared to the $45.83 million average estimate based on four analysts.Segment Income- HVAC: $108.5 million compared to the $107.68 million average estimate based on four analysts.View all Key Company Metrics for SPX Technologies here>>>

Shares of SPX Technologies have returned +10.2% over the past month versus the Zacks S&P 500 composite's -1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

For the quarter ended December 2025, Flywire (FLYW - Free Report) reported revenue of $152.7 million, up 35.4% over the same period last year. EPS came in at $0, compared to -$0.12 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $143.83 million, representing a surprise of +6.17%. The company delivered an EPS surprise of +100%, with the consensus EPS estimate being -$0.01.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Flywire performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Total Payment Volume: $9.3 billion compared to the $8.24 billion average estimate based on five analysts.Revenue- Transaction: $126.5 million compared to the $117.36 million average estimate based on four analysts. The reported number represents a change of +32.7% year over year.Revenue Less Ancillary Services- Transaction: $126 million compared to the $117.9 million average estimate based on four analysts. The reported number represents a change of +32.6% year over year.Revenue Less Ancillary Services- Platform and other revenues: $26.7 million versus $23.18 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +50% change.Revenue- Platform and other revenues: $31 million versus the four-analyst average estimate of $26.21 million. The reported number represents a year-over-year change of +39%.View all Key Company Metrics for Flywire here>>>

Shares of Flywire have returned -22.6% over the past month versus the Zacks S&P 500 composite's -1% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Insider buying is one of the best bullish indicators out there, and this AI company has seen some serious activity recently.

Insider buying is one of the best indicators of how a stock might perform in the future.

The people running a company or who sit on its board of directors know it best. How could they not? They know things an investor couldn't, like sales figures since the last quarterly report or total intangibles you can't put on a spreadsheet, like office morale.

It was once put very succinctly by investing legend Peter Lynch: "Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise."

So, if you're worried about an artificial intelligence (AI) bubble and want to know which AI companies are the real deal versus those facing a rude awakening if/when any AI bubble pops, look at what the insiders at AI companies are doing with their money.

And there is one AI company that has seen some rather promising insider activity in recent months.

Image source: Getty Images.

A force for sales, a Salesforce if you will Salesforce (CRM +4.18%) is a fundamentally strong company, but its shares have had a rough go on the market recently. The company is down 30% year to date (as of Feb. 19.

There hasn't been much insider activity recently, only four transactions with two buys and two sells, but what is there is interesting.

First was Harris Parker, the company's co-founder. His sale of $31.6 million in shares in December 2025 may look alarming at first, but that transaction was part of a 10b5-1 plan, which means it was pre-planned and unrelated to Salesforce's performance.

The only other sale (and the only discretionary sale) was from Neelie Kroes, former VP of the European Commission and a longtime Salesforce director. She sold 3,893 shares for a total of $929,276 in January 2026. As I mentioned before, though, sales like that could be for any number of reasons.

Today's Change

(

4.18

%) $

7.45

Current Price

$

185.61

On to the buyers, with two interesting transactions.

The smaller purchase involved Kirk David Blair, a company director. He bought 1,936 shares for a total of $500,722 in mid-December 2025. That's a serious vote of confidence in where Salesforce is headed in its near future.

But the biggest play was from Mason Morfit, another director and the co-chief executive officer and chief investment officer of the investment firm ValueAct Capital with $10 billion in assets under management. Or rather, his firm bought some Salesforce stock.

ValueAct purchased $25 million worth of Salesforce shares on Dec. 5 , showing serious confidence in Salesforce's future.

So, excluding the 10b5-1 sales, which didn't concern Salesforce as a company, there's net insider buying totaling just shy of $24.6 million in the past three months.

With that in mind, I am very interested in Salesforce's fiscal 2026 results, which are due to be released on Feb. 25, and its spring 2026 product release on Feb. 23, 2026, when it plans to introduce new agentic capabilities and an AI-powered Sales Workspace, among other things.

Just because company insiders know more than outside investors about what's going on behind the scenes doesn't mean they're right about everything. High insider buying activity isn't a foolproof indicator. However, combined with Salesforce's fundamental strength, I would recommend giving this one a look.

Tigo Energy, Inc. (TYGO - Free Report) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.44 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +18.26%. A quarter ago, it was expected that this company would post a loss of $0.05 per share when it actually produced a loss of $0.03, delivering a surprise of +40%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Tigo Energy, Inc., which belongs to the Zacks Solar industry, posted revenues of $30.03 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 0.32%. This compares to year-ago revenues of $17.27 million. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Tigo Energy, Inc. shares have added about 142.8% since the beginning of the year versus the S&P 500's decline of 0.1%.

What's Next for Tigo Energy, Inc.?While Tigo Energy, Inc. has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Tigo Energy, Inc. was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.08 on $26.25 million in revenues for the coming quarter and -$0.11 on $128.02 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Solar is currently in the top 34% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, FTC Solar (FTCI - Free Report) , has yet to report results for the quarter ended December 2025. The results are expected to be released on March 5.

This solar tracking systems maker is expected to post quarterly loss of $0.21 per share in its upcoming report, which represents a year-over-year change of +73.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

FTC Solar's revenues are expected to be $32.83 million, up 148.7% from the year-ago quarter.

UFP Technologies (UFPT - Free Report) came out with quarterly earnings of $2.44 per share, beating the Zacks Consensus Estimate of $2.26 per share. This compares to earnings of $2.46 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +7.81%. A quarter ago, it was expected that this packaging company and component manufacturer would post earnings of $2.22 per share when it actually produced earnings of $2.39, delivering a surprise of +7.66%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

UFP, which belongs to the Zacks Medical - Instruments industry, posted revenues of $148.92 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 1.08%. This compares to year-ago revenues of $144.07 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

UFP shares have added about 8.9% since the beginning of the year versus the S&P 500's decline of 0.1%.

What's Next for UFP?While UFP has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for UFP was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $2.55 on $156.63 million in revenues for the coming quarter and $10.58 on $635.48 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 29% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Treace Medical Concepts (TMCI - Free Report) , another stock in the same industry, has yet to report results for the quarter ended December 2025. The results are expected to be released on February 27.

This orthopedic medical device maker is expected to post quarterly loss of $0.15 per share in its upcoming report, which represents a year-over-year change of -1400%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Treace Medical Concepts' revenues are expected to be $61.77 million, down 10.1% from the year-ago quarter.

STAMFORD, Conn., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating potential breaches of fiduciary duty by the Board of Directors of MarketWise, Inc. (Nasdaq: MKTW) on behalf of the company's stockholders.

The investigation focuses on whether the MarketWise Board of Directors has fulfilled its fiduciary obligations to stockholders, including its duty of loyalty.

Stockholders who have held shares of MarketWise and are interested in learning more about the investigation or their legal rights are encouraged to contact Abbott Cooper PLLC at no cost or obligation.

Abbott Cooper PLLC handles cases on a contingency fee basis, meaning there is no cost to stockholders unless a recovery is obtained.

IF YOU ARE A MARKETWISE STOCKHOLDER AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, PLEASE CONTACT:

J. Abbott R. Cooper
Abbott Cooper PLLC
1266 East Main Street
Suite 700R
Stamford, CT 06902
(475) 477-5031
[email protected]
https://abbottlawyer.com/

Attorney Advertising. Prior results do not guarantee a similar outcome.

Tempus AI, Inc. (TEM) Q4 2025 Earnings Call Transcript

, /PRNewswire/ -- IBM (NYSE: IBM) today released the 2026 X-Force Threat Intelligence Index, revealing that cybercriminals are exploiting basic security gaps at dramatically higher rates, now accelerated by AI tools that help attackers identify weaknesses faster than ever. IBM X‑Force observed a 44% increase in attacks that began with the exploitation of public-facing applications, largely driven by missing authentication controls and AI-enabled vulnerability discovery. 

Some of the key highlights include:

IBM X-Force Threat Intelligence Index 2026 Active ransomware and extortion groups surged (49%) year over year, marking ecosystem fragmentation, while publicly disclosed victim counts rose roughly 12%. Large supply chain and third-party compromises nearly quadrupled since 2020, as attackers increasingly exploit environments where software is built and deployed or SaaS integrations. Vulnerability exploitation became the leading cause of attacks, accounting for 40% of incidents observed by X-Force in 2025. "Attackers aren't reinventing playbooks, they're speeding them up with AI," said Mark Hughes, Global Managing Partner for Cybersecurity Services, IBM. "The core issue is the same: businesses are overwhelmed by software vulnerabilities. The difference now is speed. With so many vulnerabilities requiring no credentials, attackers can bypass humans and move straight from scanning to impact. Security leaders need to shift to a more proactive approach, using agentic-powered threat detection and response to identify gaps and catch threats before they escalate."

AI's Mounting Identity Problem

Infostealer malware led to the exposure of over 300,000 ChatGPT credentials in 2025, signaling that AI platforms have reached the same credential risk as other core enterprise SaaS solutions.

Compromised chatbot credentials create AI-specific risks beyond simple account access. Attackers can manipulate outputs, exfiltrate sensitive data or inject malicious prompts. This underscores the need to assess enterprise-wide AI adoption and enforce strong authentication, and conditional access controls.

AI, Leaked Tooling Lower Barriers to Ransomware Ecosystem

In 2025, X-Force observed a 49% increase in active ransomware groups compared to the prior year, as smaller, transient operators whose low volume campaigns complicate attribution. This trend is accelerated by collapsing barriers to entry as threat actors reuse leaked tooling, rely on established playbooks and increasingly tap AI to automate operations. As multimodal AI models mature, X-Force expects adversaries to automate complex tasks like reconnaissance and advanced ransomware attacks, driving faster-moving, more adaptive threats.

Pressure on Supply Chains Poised to Grow

X-Force identified a nearly 4X increase in large supply chain or third-party compromises since 2020, mainly driven by attackers exploiting trust relationships and CI/CD automation across development workflows and SaaS integrations. With AI-powered coding tools accelerating software creation, and occasionally introducing unvetted code, the pressure on pipelines and open‑source ecosystems is expected to grow in 2026.

This rise is also attributed to the blurring line between nation-state and financially motivated actors. As tactics and techniques spread across underground forums, and AI streamlines reconnaissance and exploitation, techniques once reserved for nation-state actors are now being adopted by financially motivated groups.

Additional findings from the 2026 report include:

AI accelerating attacker lifecycle. Attackers are using AI to speed research, analyze large data sets and iterate on attack paths in real time. For example, North Korean IT worker schemes are using AI to scale operations, including AI-driven image manipulation for synthetic identities and translation tools to interact across global marketplaces. Security fundamentals still lacking. X-Force Red penetration tests reveal persistent weaknesses in credential hygiene and software configuration, with misconfigured access controls as the most common entry point for these engagements. Manufacturing tops the target list for the fifth year. The sector accounted for 27.7% of incidents observed by X-Force, with data theft being the most common. North America emerged as the most‑attacked region. Accounting for 29% of total cases observed by X-Force, and up from 24% in 2024, North America became the most attacked region for the first time in 6 years. Additional resources:

Read the full IBM X-Force Threat Intelligence Index 2026. Sign up for the IBM X-Force Threat Intelligence 2026 webinar on March 17 at 11 am ET. Connect with the IBM X-Force team for a tailored review of the findings. Read more about the report's top findings in this blog. About IBM
IBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain a competitive edge in their industries. Thousands of governments and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM's hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM's breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and consulting deliver open and flexible options to our clients. All of this is backed by IBM's long-standing commitment to trust, transparency, responsibility, inclusivity and service. Visit www.ibm.com for more information.

Media Contact:
Michele Brancati
IBM Communications
[email protected]

SOURCE IBM

Marqeta (MQ - Free Report) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.05 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +100.00%. A quarter ago, it was expected that this transaction processing services provider would post a loss of $0.01 per share when it actually produced a loss of $0.01, delivering no surprise.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Marqeta, which belongs to the Zacks Financial Transaction Services industry, posted revenues of $172.11 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.94%. This compares to year-ago revenues of $135.79 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Marqeta shares have lost about 13.9% since the beginning of the year versus the S&P 500's decline of 0.1%.

What's Next for Marqeta?While Marqeta has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Marqeta was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is breakeven on $167.54 million in revenues for the coming quarter and $0.04 on $737.73 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Financial Transaction Services is currently in the bottom 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

DLocal (DLO - Free Report) , another stock in the same industry, has yet to report results for the quarter ended December 2025. The results are expected to be released on March 18.

This online payment company is expected to post quarterly earnings of $0.18 per share in its upcoming report, which represents a year-over-year change of +20%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

DLocal's revenues are expected to be $295.98 million, up 44.7% from the year-ago quarter.

Hyliion Holdings Corp. (HYLN - Free Report) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +12.50%. A quarter ago, it was expected that this company would post a loss of $0.08 per share when it actually produced a loss of $0.08, delivering no surprise.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Hyliion, which belongs to the Zacks Automotive - Original Equipment industry, posted revenues of $0.71 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 43.04%. This compares to year-ago revenues of $1.51 million. The company has not been able to beat consensus revenue estimates over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Hyliion shares have added about 6% since the beginning of the year versus the S&P 500's decline of 0.1%.

What's Next for Hyliion?While Hyliion has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Hyliion was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.08 on $1.5 million in revenues for the coming quarter and -$0.32 on $14.25 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Automotive - Original Equipment is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Custom Truck One Source, Inc. (CTOS - Free Report) , is yet to report results for the quarter ended December 2025. The results are expected to be released on March 10.

This company is expected to post quarterly earnings of $0.09 per share in its upcoming report, which represents a year-over-year change of +125%. The consensus EPS estimate for the quarter has been revised 1.3% lower over the last 30 days to the current level.

Custom Truck One Source, Inc.'s revenues are expected to be $581.67 million, up 11.7% from the year-ago quarter.

LTC Properties (LTC - Free Report) came out with quarterly funds from operations (FFO) of $0.7 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to FFO of $0.72 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an FFO surprise of +2.32%. A quarter ago, it was expected that this real estate investment trust would post FFO of $0.65 per share when it actually produced FFO of $0.69, delivering a surprise of +6.15%.

Over the last four quarters, the company has surpassed consensus FFO estimates three times.

LTC, which belongs to the Zacks REIT and Equity Trust - Other industry, posted revenues of $26.71 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 6.02%. This compares to year-ago revenues of $34.81 million. The company has not been able to beat consensus revenue estimates over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future FFO expectations will mostly depend on management's commentary on the earnings call.

LTC shares have added about 14% since the beginning of the year versus the S&P 500's decline of 0.1%.

What's Next for LTC?While LTC has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's FFO outlook. Not only does this include current consensus FFO expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of estimate revisions.

Ahead of this earnings release, the estimate revisions trend for LTC was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus FFO estimate is $0.72 on $32.68 million in revenues for the coming quarter and $2.80 on $138.65 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, REIT and Equity Trust - Other is currently in the bottom 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, VICI Properties Inc. (VICI - Free Report) , has yet to report results for the quarter ended December 2025. The results are expected to be released on February 25.

This company is expected to post quarterly earnings of $0.60 per share in its upcoming report, which represents a year-over-year change of +5.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

VICI Properties Inc.'s revenues are expected to be $1.02 billion, up 4.1% from the year-ago quarter.

Corcept Therapeutics (CORT - Free Report) came out with quarterly earnings of $0.2 per share, missing the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.26 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -24.53%. A quarter ago, it was expected that this drug developer would post earnings of $0.18 per share when it actually produced earnings of $0.16, delivering a surprise of -11.11%.

Over the last four quarters, the company has surpassed consensus EPS estimates just once.

Corcept, which belongs to the Zacks Medical - Drugs industry, posted revenues of $202.13 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 20.54%. This compares to year-ago revenues of $181.89 million. The company has not been able to beat consensus revenue estimates over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Corcept shares have added about 1.6% since the beginning of the year versus the S&P 500's decline of 0.1%.

What's Next for Corcept?While Corcept has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Corcept was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.26 on $195.52 million in revenues for the coming quarter and $0.72 on $1.03 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Aclaris Therapeutics (ACRS - Free Report) , is yet to report results for the quarter ended December 2025.

This specialty pharmaceutical company is expected to post quarterly loss of $0.15 per share in its upcoming report, which represents a year-over-year change of -50%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Aclaris Therapeutics' revenues are expected to be $1.93 million, down 79% from the year-ago quarter.

FrontView REIT, Inc. (FVR - Free Report) came out with quarterly funds from operations (FFO) of $0.31 per share, in line with the Zacks Consensus Estimate . This compares to FFO of $0.27 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an FFO surprise of +1.08%. A quarter ago, it was expected that this company would post FFO of $0.3 per share when it actually produced FFO of $0.32, delivering a surprise of +6.67%.

Over the last four quarters, the company has surpassed consensus FFO estimates four times.

FrontView REIT, Inc., which belongs to the Zacks REIT and Equity Trust - Other industry, posted revenues of $16.52 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 2.97%. This compares to year-ago revenues of $16.87 million. The company has not been able to beat consensus revenue estimates over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future FFO expectations will mostly depend on management's commentary on the earnings call.

FrontView REIT, Inc. shares have added about 11.6% since the beginning of the year versus the S&P 500's decline of 0.1%.

What's Next for FrontView REIT, Inc.?While FrontView REIT, Inc. has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's FFO outlook. Not only does this include current consensus FFO expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of estimate revisions.

Ahead of this earnings release, the estimate revisions trend for FrontView REIT, Inc. was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus FFO estimate is $0.31 on $17.66 million in revenues for the coming quarter and $1.29 on $74.32 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, REIT and Equity Trust - Other is currently in the bottom 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Hudson Pacific Properties (HPP - Free Report) , another stock in the same industry, has yet to report results for the quarter ended December 2025. The results are expected to be released on February 26.

This real estate investment trust is expected to post quarterly earnings of $0.20 per share in its upcoming report, which represents a year-over-year change of -74%. The consensus EPS estimate for the quarter has been revised 26.8% lower over the last 30 days to the current level.

Hudson Pacific Properties' revenues are expected to be $189.59 million, down 9.6% from the year-ago quarter.